Accumen, which assists organizations with outreach services, imaging, clinical laboratory operations and patient blood management, has acquired Halfpenny Technologies, a clinical data exchange company.

Financial terms of the deal were not disclosed.

Read on original publication

With offices in San Diego and Phoenix, Accumen, which was founded in 2011, partners with hospitals and health systems to improve clinical laboratories and patient blood management programs. Its strategy focuses on cost containment, revenue growth and improving quality. The company’s clients include Sharp HealthCare, Detroit Medical Center, Children’s Hospital Colorado and Wake Forest Baptist Health.

In January 2019, private equity firm Arsenal Capital Partners acquired Accumen. Financial details of that deal weren’t disclosed.

Halfpenny Technologies was founded in 2000 and is headquartered in Blue Bell, Pennsylvania. It provides cloud-based, vendor-neutral clinical data exchange and business intelligence solutions to a variety of entities, including health systems, commercial labs, health plans, pharmacies and others. The goal is to improve clients’ interoperability so they can drive better care coordination.

Back in 2010, Halfpenny secured $2.6 million in a funding round led by Osage Venture Partners and Milestone Venture Partners. LORE Associates also participated.

Additionally, the company raised $2.25 million in 2012. That round was led by Emerald Stage2 Ventures and Vital Financial. Osage Venture Partners, Milestone Venture Partners and LORE Associates took part as well.

Halfpenny and Accumen have already been business partners for seven years, according to a news release.

Through the acquisition, Accumen will add core competencies to its portfolio.

“Halfpenny’s focus on data performance uniquely connects to Accumen’s clinical and operational performance-based partnership approach,” said Accumen CEO Jeff Osborne in a statement. “When we look to the future of what our customers see as their greatest areas of need, our work with Halfpenny will be integral in supporting the next evolution of health and patient care.”